Neoplastic disease or syndrome
MONDO:0023370Either an isolated neoplasm or a syndrome with neoplasm as a major feature.
Also known as: neoplastic disease, neoplastic disorder
31093 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 4030 trials in this tab.
-
Can a single gene therapy turn the body into a Cancer-Fighting factory?
⭐️ CURE ⭐️ Not yet recruitingThis phase 1 trial is testing a new gene therapy called UB-VV500 for people with multiple myeloma that has returned or stopped responding to treatment. The therapy works by giving the body genetic instructions to produce its own CAR T cells that target two proteins on myeloma cel…
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 03:00 UTC
-
Can a Two-Drug punch erase penile cancer before surgery?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether combining two drugs—pucotenlimab, which helps the immune system attack cancer, and becotatug vedotin, which delivers a toxin directly to tumor cells—can eliminate advanced penile cancer before surgery. Men with high-risk, locally advanced penile squamous …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 03:00 UTC
-
Can a single shot build a cancer army inside the body?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…
Phase: PHASE1, PHASE2 • Sponsor: Umoja Biopharma • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 03:00 UTC
-
Can a Two-Drug punch shrink oral tumors before surgery?
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial is testing whether giving two drugs before surgery can help people with advanced oral cavity cancer. The drugs, becotatug vedotin and pucotenlimab, are designed to attack cancer cells and boost the immune system. Participants receive three cycles of the combina…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 03:00 UTC
-
Can a Slow-Release chemo implant tackle an untreatable brain tumor?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing whether a new formulation of the chemotherapy drug cisplatin, called LSAM-Cisplatin, can be safely infused directly into the brain tumors of children and young adults with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The t…
Phase: PHASE1, PHASE2 • Sponsor: NanOlogy, LLC • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 03:00 UTC
-
Can your own immune cells beat advanced cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase: PHASE1, PHASE2 • Sponsor: Gritbio Medicine, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug combo make stem cell transplants safer for frail AML patients?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing whether a new conditioning regimen, called VABu, can improve outcomes for adults with acute myeloid leukemia (AML) who are in first remission but are too frail for standard transplant prep. The regimen combines venetoclax, azacitidine (or decitabine), and bu…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
⭐️ CURE ⭐️ Not yet recruitingThis phase 1 trial is testing an experimental therapy called CD19/CD20 dual-target in vivo CAR-T for people with relapsed or refractory B-cell malignancies—blood cancers that have not responded to standard treatments. The approach uses a lentiviral product to engineer a patient's…
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat myeloma
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…
Phase: PHASE1, PHASE2 • Sponsor: UCARsgen Biotech Limited • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Engineered donor cells could outsmart relapsed myeloma
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T c…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug combo reset the immune system to beat relapsed leukemia?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether a combination of sonrotoclax, cladribine, and cytarabine, followed by a stem cell transplant, can improve survival in adults with relapsed or refractory acute myeloid leukemia (AML). Participants receive the chemotherapy regimen, then undergo an allogenei…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can engineered immune cells outsmart resistant blood cancers?
⭐️ CURE ⭐️ Not yet recruitingThis early-stage trial is investigating whether a new type of CAR T-cell therapy, which targets a protein called BAFFR on cancer cells, can safely and effectively treat adults with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma that has returned or not respo…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Bladder cancer: a new combo aims to avoid radical surgery
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether combining two drugs—disitamab vedotin and toripalimab—with or without pelvic lymph node removal can help people with muscle-invasive bladder cancer keep their bladder. Participants, who have HER2-positive tumors and decline bladder removal surgery, will r…
Phase: PHASE2, PHASE3 • Sponsor: Tianjin Medical University Second Hospital • Aim: ⭐️ CURE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
Can a pill restore the Body's tumor suppressor to fight multiple cancers?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…
Phase: PHASE1, PHASE2 • Sponsor: LG Chem • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Can your own immune cells fight advanced cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…
Phase: PHASE1, PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill and injection combo beat AML without harsh chemo?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests a combination of two drugs, azacitidine and venetoclax, as the first treatment for young, fit adults (ages 18-50) with newly diagnosed acute myeloid leukemia (AML). The goal is to see how many patients achieve complete remission after one or two cycles of this th…
Phase: PHASE2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: ⭐️ CURE ⭐️
Last updated Aug 07, 2026 00:00 UTC
-
Could a blast of argon plasma wipe out cervical precancer without surgery?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The m…
Phase: NA • Sponsor: University Hospital Tuebingen • Aim: ⭐️ CURE ⭐️
Last updated Aug 05, 2026 00:00 UTC
-
Could a single drug replace surgery for rectal cancer?
⭐️ CURE ⭐️ Not yet recruitingThis study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ CURE ⭐️
Last updated Aug 05, 2026 00:00 UTC
-
Can a poison become a cure? arsenic trioxide put to the test in blood cancer transplant
⭐️ CURE ⭐️ Not yet recruitingThis early-phase trial tests whether adding arsenic trioxide to a standard stem cell transplant can prevent the cancer from coming back in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls about 20 patients whose cancers have …
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
⭐️ CURE ⭐️ Not yet recruitingThis phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
A made-to-order DNA vaccine takes aim at liver cancer's return
⭐️ VACCINE ⭐️ Not yet recruitingThis phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…
Phase: PHASE2 • Sponsor: Geneos Therapeutics • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can a common drug boost Chemo's power against Hard-to-Treat leukemia?
Disease control Not yet recruitingThis trial is testing whether adding hydroxyurea to a standard chemotherapy combination can improve outcomes for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The study is conducted in two parts: first to find the safest dose of hydroxy…
Phase: PHASE1, PHASE2 • Sponsor: Christer C Nilsson • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New pill combo aims to tame tough leukemia
Disease control Not yet recruitingThis study tests an oral chemotherapy drug, cladribine, combined with two other drugs (low-dose cytarabine and venetoclax) in people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease. About 58 ad…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a new drug shrink Hard-to-Treat gynecological tumors?
Disease control Not yet recruitingThis phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New device could keep donor livers healthier before transplant
Disease control Not yet recruitingThis study tests a device that keeps donor livers cool and oxygenated before transplant, aiming to reduce early liver problems. About 215 first-time liver transplant patients will receive a liver preserved with this method. The goal is to see if it lowers the risk of early graft …
Phase: NA • Sponsor: XVIVO Perfusion • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase: PHASE1, PHASE2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Immune-Boosting drug and vaccine aim to fight returning prostate cancer
Disease control Not yet recruitingThis Phase II trial tests whether an immune-boosting drug (N-803) alone or combined with a vaccine (ETBX-071) can lower PSA levels in men whose prostate cancer has returned after targeted radiation therapy. Participants receive up to eight cycles of treatment and are followed for…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a smart chemo drug outsmart advanced throat cancer?
Disease control Not yet recruitingThis trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…
Phase: PHASE3 • Sponsor: Corbus Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a Double-Wall bag stop leaks during keyhole fibroid surgery?
Disease control Not yet recruitingThis trial tests whether the LapBox Manual Containment System, a double-wall bag used during laparoscopic surgery, can prevent leaks when removing uterine fibroids. About 30 women having laparoscopic hysterectomy or myomectomy will use the device, and surgeons will check for any …
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Liver tumors targeted directly: old pump, new drug
Disease control Not yet recruitingThis trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Personalized stem cell transplant aims to beat inherited blood cancers
Disease control Not yet recruitingThis study tests whether adjusting chemotherapy doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by a RUNX1 gene mutation. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goa…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a Bag-Like device pull bladder tumors out whole?
Disease control Not yet recruitingThis trial tests a new tool called CURTIS, designed to safely remove bladder tumors in one intact piece after they are cut out during surgery. The goal is to see how often the device can successfully retrieve the tumor without breaking it apart, and what the largest tumor size is…
Phase: NA • Sponsor: Ludwig-Maximilians - University of Munich • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can Long-Term tucatinib use remain safe for HER2-Positive cancers?
Disease control Not yet recruitingThis study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Radioactive drug targets Hard-to-Treat thyroid cancer
Disease control Not yet recruitingThis study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?
Disease control Not yet recruitingThis phase II trial tests whether combining bevacizumab, a drug that limits blood vessel growth, with PRGN-2012, a vaccine-based therapy, can help adults with recurrent respiratory papillomatosis (RRP) avoid needing more surgeries. RRP causes wart-like growths in the airway that …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New drug targets pancreatic cancer before surgery
Disease control Not yet recruitingThis early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
Disease control Not yet recruitingThis trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…
Phase: PHASE2 • Sponsor: Yongsheng Wang • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can MRI-Guided radiation offer a safer way to treat kidney cancer?
Disease control Not yet recruitingThis trial is testing whether MRI-guided radiation therapy can treat early-stage kidney cancer with fewer side effects than standard CT-based radiation. The study enrolls adults with kidney cancer who are not candidates for surgery or who decline it. Participants receive a single…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a Weight-Loss drug shield breast cancer Survivors' hearts?
Disease control Not yet recruitingThis trial tests whether adding semaglutide to structured lifestyle counseling improves heart and blood vessel health in postmenopausal breast cancer survivors with obesity who are taking an aromatase inhibitor. Participants will receive either semaglutide or a placebo, along wit…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New hope for Hard-to-Treat endometrial cancer: pfizer launches phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their ca…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Experimental cell therapy takes on tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can a new immunotherapy combo tame aggressive appendiceal cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can MRI-Guided radiation zero in on prostate tumors with fewer side effects?
Disease control Not yet recruitingThis trial is testing a new way to deliver radiation therapy for prostate cancer. Instead of standard radiation, it uses MRI to precisely target the tumor, potentially sparing healthy tissue and reducing side effects. The study will include about 20 adults with early-stage prosta…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Personalized lymphoma therapy: could lower radiation be enough?
Disease control Not yet recruitingThis trial is testing a personalized approach for people with early-stage extranodal NK/T-cell lymphoma, a rare cancer of the immune system. All participants receive two cycles of induction chemotherapy (GELAD), then doctors check how well the tumor responded using a PET/CT scan …
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could a workout plan shield the heart during prostate cancer therapy?
Disease control Not yet recruitingThis trial tests whether a supervised strength and conditioning program can protect the heart and reduce inflammation in men with prostate cancer who are receiving radiation and hormone therapy. Participants will follow a structured exercise routine, and researchers will measure …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can Pre-Surgery rehab ease recovery from tumor bowel blockage?
Disease control Not yet recruitingThis trial tests whether a multimodal prehabilitation program—combining exercise, nutrition, and psychological support—can improve outcomes for patients with tumor-related bowel obstruction. Participants are randomly assigned to receive either this program plus postoperative immu…
Phase: NA • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New vaccine combo aims to halt prostate cancer growth without surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can an immunotherapy combo turn inoperable gallbladder cancer into a surgical success?
Disease control Not yet recruitingThis phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder …
Phase: PHASE2 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
New cell therapy B019 takes on tough lymphoma in first human trial
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.
Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a hormone mimic curb the need for bloodletting in a blood cancer?
Disease control Not yet recruitingThis trial tests whether rusfertide, a synthetic version of the hormone hepcidin, can help people with polycythemia vera—a condition where the bone marrow makes too many red blood cells—by lowering iron availability and keeping red blood cell counts in check. The study enrolls Ch…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Heat treatment after polyp removal may slash regrowth risk
Disease control Not yet recruitingThis study tests whether adding a heat treatment (thermal ablation) to the standard procedure for removing large colon polyps can lower the chance they grow back. About 752 adults will be randomly assigned to receive either standard removal alone or standard removal plus burning …
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Dual-Action antibody boost chemo against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…
Phase: PHASE2, PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
Disease control Not yet recruitingThis phase 3 trial is testing whether a radioactive drug called iopofosine I 131 can keep Waldenstrom macroglobulinemia (a rare blood cancer) from getting worse for longer than the standard combination of rituximab, cyclophosphamide, and dexamethasone (R-CD). The study enrolls ab…
Phase: PHASE3 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can heated chemotherapy beat bladder cancer without surgery?
Disease control Not yet recruitingThis trial is testing a device that delivers heated chemotherapy directly into the bladder for people with non-muscle invasive bladder cancer. The goal is to see if the system is safe and works as intended. Participants will receive the treatment and be monitored for side effects…
Phase: NA • Sponsor: Eight Medical International BV • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
Disease control Not yet recruitingThis phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuz…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can AI-Guided home training boost recovery from gastric cancer surgery?
Disease control Not yet recruitingThis trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…
Phase: NA • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can sound waves supercharge immunotherapy against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo shows promise for aggressive lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (DA-EPOCH-R) helps people with high-risk Burkitt lymphoma. About 43 adults will receive the combination. The study will check how many complete at least three cycles of treatment and track overa…
Phase: PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug help when standard therapy falls short for prostate cancer?
Disease control Not yet recruitingThis phase 2 trial is testing an experimental drug called xaluritamig in men with metastatic castrate-resistant prostate cancer who had only a partial or stable response to lutetium-177 therapy. The goal is to see if xaluritamig can shrink tumors or lower PSA levels. About 30 par…
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Triple-Action antibody deepen remissions in myeloma?
Disease control Not yet recruitingThis phase II trial is testing whether a new investigational drug called IBI3003, when combined with an existing anti-CD38 antibody (daratumumab), can improve outcomes for people with multiple myeloma. The study includes patients with relapsed or refractory disease, as well as ne…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can diet and vitamin c supercharge rectal cancer treatment?
Disease control Not yet recruitingThis phase 2 trial is investigating whether adding a ketogenic diet and/or high-dose intravenous vitamin C to standard chemoradiotherapy and immunotherapy can improve outcomes for patients with locally advanced rectal cancer that is mismatch repair proficient (pMMR/MSS). The stud…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Smart missile drug takes aim at Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThis trial tests a new medicine called SOT109 for people with advanced colorectal cancer that cannot be removed by surgery or has spread. SOT109 is designed to find and attack cancer cells that have a specific marker (CDH17) while sparing healthy cells. The study has two parts: t…
Phase: PHASE1, PHASE2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can an immune booster outsmart brain lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug called penpulimab to a standard chemotherapy regimen can help people with primary central nervous system lymphoma, a rare type of brain cancer. Participants, who have not yet received treatment, are randomly assigned to r…
Phase: NA • Sponsor: WEI XU • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Lung cancer breakthrough: could observation replace surgery?
Disease control Not yet recruitingThis pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…
Phase: PHASE1 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could avoiding Pre-Radiation tooth removal protect jaw health?
Disease control Not yet recruitingThis trial asks whether it is safe to skip the routine removal of impacted teeth before radiation therapy for nasopharyngeal carcinoma. Half of the participants will have the extraction as usual, while the other half will not. The study will compare the risk of jaw bone damage (o…
Phase: NA • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Custom-Made vaccine train the immune system to fight brain cancer?
Disease control Not yet recruitingThis early-stage trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with standard chemotherapy and immunotherapy drugs. The goal is to see if this multi-pronged approach can safely and effectively boost the immun…
Phase: PHASE1, PHASE2 • Sponsor: BreakBio Corp • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
Disease control Not yet recruitingThis early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…
Phase: PHASE1, PHASE2 • Sponsor: BreakBio Corp • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Dual-Pronged antibody outsmart advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a daily pill tame rare cancers in teens? new trial investigates
Disease control Not yet recruitingThis phase 2 trial tests the safety of belzutifan, a daily oral tablet, in adolescents with rare solid tumors that cannot be surgically removed or have spread. The study includes three tumor types: pheochromocytoma/paraganglioma (PPGL), wild-type gastrointestinal stromal tumors (…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Triple therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for HIV patients with aggressive lymphoma: early trial launches
Disease control Not yet recruitingThis early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new infusion drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the …
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a cold snare match heat for polyp removal?
Disease control Not yet recruitingThis trial compares two endoscopic techniques for removing flat, non-cancerous colorectal polyps that are 10-20 mm in size. One method uses a cold snare (no heat), while the other uses a hot snare with electrocautery. The goal is to see if the cold approach is just as effective a…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can switching cancer therapy early extend life in stomach cancer?
Disease control Not yet recruitingThis trial is testing whether switching to a different drug combination after initial chemotherapy can help people with advanced gastroesophageal cancer live longer without the disease worsening. Participants first receive standard chemotherapy plus an immunotherapy drug (tisleli…
Phase: PHASE3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Hormone-Blocking drug boost chemo against cervical cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Zapping resistant spots: radiation may buy more time for lung cancer patients on targeted drugs
Disease control Not yet recruitingThis study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New biosimilar aims to match opdivo for melanoma
Disease control Not yet recruitingThis study tests whether a new drug called Bmab1700 works the same as the approved immunotherapy Opdivo in people with melanoma who have had their tumors surgically removed. The trial will involve 120 adults with stage IIB to IV melanoma. Researchers will compare how the drugs mo…
Phase: PHASE1 • Sponsor: Biocon Biologics UK PLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New shot aims to stop hidden leukemia in its tracks
Disease control Not yet recruitingThis study tests whether a drug called blinatumomab, given as a simple injection under the skin, can control small amounts of leftover leukemia cells (called measurable residual disease, or MRD) in adults with B-cell acute lymphoblastic leukemia. The goal is to prevent the cancer…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can umbilical cord blood keep leukemia at bay in older patients?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding an umbilical cord blood infusion to standard consolidation chemotherapy can help older adults with intermediate- or high-risk acute myeloid leukemia (AML) stay free of relapse. About 132 patients aged 60 to 80 who achieved remission af…
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Immune cells injected into spine to fight brain cancer
Disease control Not yet recruitingThis early-phase trial tests whether immune cells (CD8+ T cells) given through a spinal tap are safe for people with melanoma that has spread to the lining of the brain. Only 8 participants will receive the treatment. The main goal is to check for side effects, not to cure the di…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Promising combo targets tough leukemia
Disease control Not yet recruitingThis study tests a new way to treat a fast-growing blood cancer called BCR-ABL positive B-cell acute lymphoblastic leukemia. About 80 adults will receive two drugs: ponatinib pills and blinatumomab injections under the skin. The goal is to see if this combination can control the …
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Smart blood test guides treatment for stubborn hodgkin lymphoma
Disease control Not yet recruitingThis study tests a combination of the immunotherapy drug pembrolizumab and three chemotherapy drugs (GVD) in 38 adults whose Hodgkin lymphoma returned or did not respond to one prior treatment. A special blood test (ctDNA) is used to see how well the treatment is working and to g…
Phase: PHASE2 • Sponsor: Michael Spinner, MD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could cutting salt after childbirth tame dangerous blood pressure?
Disease control Not yet recruitingThis trial tests whether a low-sodium diet can improve blood pressure control in people who had a hypertensive disorder of pregnancy. Participants receive either a provided diet with less than 2000 mg of sodium per day or a standard diet with no salt restrictions for the first we…
Phase: NA • Sponsor: Women and Infants Hospital of Rhode Island • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug trial targets rare nasal cancer
Disease control Not yet recruitingThis phase 2 study tests the drug zanzalintinib in 16 adults with recurrent or metastatic olfactory neuroblastoma, a rare cancer of the nasal cavity. The goal is to see if the drug can help control the disease and to check its safety. Participants must not have had prior treatmen…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Blood test may tailor lung cancer immunotherapy, sparing unnecessary treatment
Disease control Not yet recruitingThis trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Two apps battle to help smokers kick the habit
Disease control Not yet recruitingThis study compares two smartphone apps designed to help people stop smoking. One app uses a therapy that focuses on mood and behavior, while the other uses standard quitting advice. About 1,800 adult smokers who want to quit in the next month will use one of the apps for 30 days…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug combo shrink liver tumors?
Disease control Not yet recruitingThis study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevac…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
Disease control Not yet recruitingThis trial tests whether an AI tool called SurgDiff can predict how difficult rectal cancer surgery will be, based on MRI scans and patient data. The goal is to help surgeons choose the best surgical approach for each patient, potentially reducing complications. The study involve…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a drug combo outsmart a tough breast cancer subtype?
Disease control Not yet recruitingThis phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A nudge in time: could text reminders boost alcohol care for cancer patients?
Disease control Not yet recruitingThis trial tests whether simple reminders—sent to patients' phones and to their care teams—can increase the use of alcohol screening and brief counseling (SBIRT) during cancer care. About 315 adults with cancer across four clinics will take part, with some clinics using the remin…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can an experimental drug stop polyps from coming back in a rare inherited condition?
Disease control Not yet recruitingThis phase 1b trial tests an experimental drug called ST316 in adults with familial adenomatous polyposis (FAP) who have already had their colon removed but still develop new polyps. The study aims to see if ST316 is safe and can reduce the number and size of polyps that grow bac…
Phase: PHASE1 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo keep aggressive lymphoma at bay?
Disease control Not yet recruitingThis trial is testing whether a combination of pomalidomide (a pill) and rituximab (an infusion) can help young adults with high-risk diffuse large B-cell lymphoma (DLBCL) stay in remission after their first round of treatment. Participants, who must be under 60 and have responde…
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced melanoma: immunotherapy combo tested in india
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, in people with advanced melanoma that hasn't been treated before. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults and teens (ages 12 and up) in India will t…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo tackles tough leukemia
Disease control Not yet recruitingThis early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand si…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug outperform standard care for head and neck cancer?
Disease control Not yet recruitingThis trial is testing whether an experimental drug called SYS6010 can better control advanced head and neck cancer compared to standard single-drug treatments. It involves about 340 adults aged 18-75 whose cancer has returned or spread and who have already tried platinum-based ch…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug spare healthy cells while killing lymphoma?
Disease control Not yet recruitingThis trial is testing an experimental drug called FG-M131 in people with a type of blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. FG-M131 is designed to target and destroy cancerous T cells that carry a marker called TRBC1, …
Phase: PHASE1, PHASE2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new Armpit-Incision technique make breast reconstruction safer and easier?
Disease control Not yet recruitingThis study compares two ways to rebuild a breast after a mastectomy for breast cancer: a newer, minimally invasive endoscopic method done through a small armpit incision, versus the traditional latissimus dorsi flap surgery (using muscle from the back, often with an implant). The…
Sponsor: Du Zhenggui • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Steam therapy aims to zap prostate cancer without major surgery
Disease control Not yet recruitingThis study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with Grade Group 3 intermediate-risk prostate cancer. Fifty participants will receive the treatment and be followed for two years to see if the cancer is reduced and t…
Phase: NA • Sponsor: Francis Medical Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for brain tumor patients when standard drug fails
Disease control Not yet recruitingThis study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…
Phase: PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Poop pills may help revive immunotherapy in lung cancer patients
Disease control Not yet recruitingThis study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …
Phase: PHASE2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new drug combo outperform standard therapy for lung cancer?
Disease control Not yet recruitingThis phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can an AI eye guide surgeons to safer, faster cancer removal?
Disease control Not yet recruitingThis trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the partici…
Phase: NA • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant myeloma?
Disease control Not yet recruitingThis phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior trea…
Phase: PHASE2 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy aims to treat leukemia without harsh chemo
Disease control Not yet recruitingThis study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
Disease control Not yet recruitingThis trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a seizure drug outsmart a deadly brain tumor?
Disease control Not yet recruitingThis trial tests whether adding levetiracetam, a seizure medication, to the standard treatment for glioblastoma can improve outcomes. Glioblastoma is an aggressive brain cancer with poor survival despite current therapy. The study focuses on tumors with low oxygen levels, which a…
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for lung cancer patients with lung scarring: trial tests safer treatments
Disease control Not yet recruitingThis study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first t…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a common heart drug treat kaposi sarcoma?
Disease control Not yet recruitingThis phase 2 trial tests whether propranolol, a drug usually used for high blood pressure, can treat Kaposi sarcoma. About 25 children and adults will take propranolol pills for up to 24 weeks. Researchers will measure how many participants see their tumors shrink or disappear, a…
Phase: PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increas…
Phase: PHASE2 • Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can less radiation be just as effective for early breast cancer?
Disease control Not yet recruitingThis trial is testing whether treating only part of the breast with radiation is as effective as treating the whole breast in women with early-stage, low-risk breast cancer. Participants are women aged 40 and older who had breast-conserving surgery and did not have a sentinel lym…
Phase: PHASE3 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can donor immune cells tame stem cell transplant risks?
Disease control Not yet recruitingThis trial tests whether an experimental cell therapy called agenT-797 is safe for people receiving a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Participants get an infusion of agenT-797 about a week after their transplant. The main goal is …
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Virtual patients could revolutionize cancer drug testing
Disease control Not yet recruitingThis trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new pill outsmart Treatment-Resistant blood cancer?
Disease control Not yet recruitingThis phase III trial is testing whether an experimental drug called TQB3909 can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) whose disease has returned or stopped responding to prior treatments. Participants will be randomly assigned to re…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining an experimental antibody called SSGJ-612 with a targeted chemotherapy (an antibody-drug conjugate) can shrink tumors in people with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer. The study enrolls ab…
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
PET scans may predict which breast cancer patients benefit from elacestrant
Disease control Not yet recruitingThis trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for myeloma patients who relapse after CAR t: bispecific antibody trial launches
Disease control Not yet recruitingThis phase 2 trial tests a drug called linvoseltamab in 34 people with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. Linvoseltamab is a bispecific antibody that helps the immune system attack myeloma cells. The main goal is to see how many patients respond…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can immunotherapy shrink Betel-Nut oral tumors before surgery?
Disease control Not yet recruitingThis trial tests whether giving two immunotherapy drugs—pembrolizumab and cetuximab—before surgery can shrink advanced oral cancers linked to betel-nut chewing. The study enrolls 20 people in the Northern Mariana Islands who have not yet received treatment. Researchers will measu…
Phase: PHASE2 • Sponsor: Peter Brett, MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new pill outperform chemotherapy for a Hard-to-Treat lung cancer mutation?
Disease control Not yet recruitingThis trial is testing whether an experimental oral drug, HS-10504, can slow the progression of advanced non-small cell lung cancer in people whose tumors carry a specific EGFR C797S mutation and have already failed prior EGFR inhibitor therapy. Participants will be randomly assig…
Phase: PHASE3 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a targeted drug combo outsmart advanced head and neck cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to the standard immunotherapy pembrolizumab can better control recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls adults whose tumors express a speci…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for young adults with CML: asciminib under Real-World scrutiny
Disease control Not yet recruitingThis study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can immune checkpoint drugs fight cancers beyond their approved uses?
Disease control Not yet recruitingThis phase 2 trial investigates whether immune checkpoint inhibitors—medicines that help the immune system attack cancer—can be effective when used off-label for different types of malignancies. Adults with cancer whose doctor is considering such treatment may join. Participants …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for tough myeloma: early trial of BP2202 begins
Disease control Not yet recruitingThis early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…
Phase: PHASE1 • Sponsor: BrightPath Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could cutting one amino acid make rectal cancer treatment more effective?
Disease control Not yet recruitingThis trial tests whether an arginine-free diet, given as a liquid formula for four weeks, can enhance the effects of standard chemoradiotherapy in people with locally advanced rectal cancer. The study first checks the diet's safety in a small group, then randomly assigns about 13…
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
Disease control Not yet recruitingThis trial is testing whether a special type of radiation called radscopal radiotherapy—which combines low-dose radiation to the main tumor and precise high-dose radiation to distant metastases—can enhance the effects of two immunotherapy drugs (sintilimab and ipilimumab) in peop…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart pancreatic cancer?
Disease control Not yet recruitingThis early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of …
Phase: PHASE1 • Sponsor: Synnovation Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart resistant leukemia?
Disease control Not yet recruitingThis trial tests whether adding gilteritinib to the standard drugs azacitidine and venetoclax can help adults with a type of acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. Participants receive the three-drug combination in repeated 28-day…
Phase: PHASE2 • Sponsor: Florian Kuchenbauer • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Organ transplant may offer new hope for rare abdominal cancer patients
Disease control Not yet recruitingThis study tests whether an intestinal or multivisceral transplant can help people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that cannot be removed by surgery. Twenty participants will receive the transplant and be followed for 12 months to see if they surv…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a vaccine plus immune booster tackle resistant prostate cancer?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two immune-based treatments—Sipuleucel-T, a vaccine made from a patient's own immune cells, and N-803, a drug that boosts immune activity—is safe and tolerable for men with metastatic prostate cancer that has stopped responding …
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug combo outperform standard care for a tough blood cancer?
Disease control Not yet recruitingThis trial is testing whether adding the drug venetoclax to different chemotherapy regimens can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It compares three experimental combinations against the standard treatment in 320 patients aged 14 and ol…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New CAR t combo takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see…
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
Disease control Not yet recruitingThis phase III trial is testing whether regular antibody infusions (immunoglobulin replacement therapy) can prevent infections better than standard antibiotic prophylaxis in people who have received CAR-T cell therapy for B-cell acute lymphoblastic leukemia or B-cell lymphoma. CA…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can adding lenvatinib to standard care outsmart a tough brain cancer?
Disease control Not yet recruitingThis phase II trial is asking whether adding the drug lenvatinib to the standard STUPP regimen (temozolomide plus radiation) can improve outcomes for people newly diagnosed with a type of brain cancer called glioblastoma that has a specific genetic marker (MGMT promoter methylati…
Phase: PHASE2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
Disease control Not yet recruitingThis trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works bette…
Phase: PHASE2, PHASE3 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a One-Two punch shrink fibroids better?
Disease control Not yet recruitingThis trial tests whether adding a chemical injection to microwave ablation improves treatment for uterine fibroids, common non-cancerous tumors that can cause heavy bleeding and pain. Microwave ablation uses heat to destroy fibroid tissue, but blood flow can cool the area and red…
Phase: NA • Sponsor: Peking University Aerospace Center Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Fish oil supplement aims to help head and neck cancer patients through tough treatment
Disease control Not yet recruitingThis pilot study will test whether a fish oil-enriched nutritional supplement, combined with weekly nutrition counseling, is feasible and safe for people with head and neck cancer undergoing chemoradiotherapy. Fifteen participants will start taking the supplement two weeks before…
Phase: PHASE1, PHASE2 • Sponsor: Anna Arthur, PhD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug boost the fight against esophageal cancer?
Disease control Not yet recruitingThis clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can Gene-Edited immune cells tame Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…
Phase: PHASE1, PHASE2 • Sponsor: CoRegen, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
Disease control Not yet recruitingThis phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo could cut hormone therapy time for prostate cancer patients
Disease control Not yet recruitingThis study tests whether adding a radioactive drug called 177Lu-PSMA-617 to standard radiation therapy can allow men with high-risk localized prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to see if this approach is as effect…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug boost Chemotherapy's power against a rare lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy can improve outcomes for people with a rare type of lymphoma called nodal T-follicular helper cell lymphoma. The study will include about 47 adults who have not yet received treatment fo…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug (PD-1 antibody) to standard treatment can improve outcomes for people with recurrent head and neck cancer. Participants will be randomly assigned to receive either the immunotherapy before and after surgery, or standard s…
Phase: PHASE2 • Sponsor: Yanjie Zhang, MD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Dual-Pronged antibody outsmart advanced cancers?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in people with locally advanced or metastatic breast cancer and other solid tumors. The study aims to find the safest dose and understand how the drug b…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug combo outsmart triple-negative breast cancer?
Disease control Not yet recruitingThis phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a pill reach the brain and fight tumors?
Disease control Not yet recruitingThis trial tests an oral drug called JBI-778 in people with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The drug is designed to block a protein that may help tumors grow. The study aims to find the safest dose and see if the drug can shrink tumors or…
Phase: PHASE1, PHASE2 • Sponsor: Jubilant Therapeutics Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A new hope for MDS patients: could this drug cut blood transfusions?
Disease control Not yet recruitingThis study looks at whether luspatercept, a drug given as first-line treatment, can help adults with low-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Researchers will follow about 190 participants for up to 2 years to see how often they achie…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug turn the tide on Hard-to-Treat blood conditions?
Disease control Not yet recruitingThis trial is testing an experimental drug called REGN17235 in people with two related blood conditions: clonal cytopenia of undetermined significance (CCUS) and low-risk myelodysplastic syndrome (MDS), both linked to a specific genetic change called an SF3B1 mutation. The main g…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can an immunotherapy combo shrink head and neck tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether adding the immunotherapy drug finotonlimab to chemotherapy before and after surgery can improve outcomes for people with stage II head and neck squamous cell carcinoma. Participants will receive either standard treatment (surgery plus chemoradiothera…
Phase: PHASE2 • Sponsor: Yanjie Zhang, MD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
Disease control Not yet recruitingThis phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side ef…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
Disease control Not yet recruitingThis phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can an immunotherapy combo shrink throat tumors before surgery?
Disease control Not yet recruitingThis phase 2 trial is testing whether giving the immunotherapy drug penpulimab together with chemotherapy before surgery can help people with locally advanced hypopharyngeal carcinoma, a type of head and neck cancer. The study will include about 15 adults aged 18 to 80 with resec…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug combo outsmart an aggressive lymphoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the targeted drug pirtobrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people newly diagnosed with a specific, harder-to-treat subtype of diffuse large B-cell lymphoma (Non-GCB DLBCL). The study will e…
Phase: PHASE2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a 'Universal' cancer target outsmart resistant blood cancers?
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…
Phase: PHASE1, PHASE2 • Sponsor: Vitruviae • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Laser zaps spine tumors without open surgery – new study launches
Disease control Not yet recruitingThis study tests a laser treatment for tumors that have spread to the spine. The goal is to see if the laser can control tumor growth as well as traditional surgery, but with less risk. About 25 people with spine tumors will receive the laser treatment and be followed with MRI sc…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Liver cancer trial aims to boost immunotherapy with targeted chemo
Disease control Not yet recruitingThis phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
Disease control Not yet recruitingThis trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…
Phase: PHASE2 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Two-Drug combo stop colorectal cancer from coming back?
Disease control Not yet recruitingThis phase 3 trial is testing whether the experimental drug zanzalintinib, alone or combined with an immunotherapy (pembrolizumab plus berahyaluronidase alfa), can improve disease-free survival in people with stage II or III colorectal cancer who have molecular residual disease (…
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug boost standard chemo for aggressive lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding pirtobrutinib, a targeted drug, to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific subtype of diffuse large B-cell lymphoma (non-GCB DLBCL). The study will enroll about 34 adults with newly diagnosed di…
Phase: PHASE2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Ready-Made immune cells take on blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with …
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a drug duo outsmart ALK-Positive lung cancer?
Disease control Not yet recruitingThis trial is testing whether combining two targeted therapies—lorlatinib and sacituzumab tirumotecan—can better control advanced ALK-positive non-small cell lung cancer when used as the first treatment. The study involves about 153 adults with locally advanced or metastatic dise…
Phase: PHASE2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radiation drug targets tough cancers in early trial
Disease control Not yet recruitingThis early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene test may guide smarter chemo for pancreatic cancer
Disease control Not yet recruitingThis phase II trial tests whether choosing chemotherapy based on a specific gene mutation (SMAD4) can improve outcomes for people with pancreatic cancer that is or may be surgically removable. The SMAD4 gene normally acts as a brake on tumor growth, but when it's mutated, tumors …
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Action antibody outsmart advanced solid tumors?
Disease control Not yet recruitingThis phase 1 trial is evaluating an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study will enroll about 30 adults with locally advanced or metastatic urological tumors or other solid tumors. The main goals are to…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Action drug combo outsmart advanced liver cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatoce…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase: PHASE1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Stomach cancer trial combines chemo and quick radiation to boost remission
Disease control Not yet recruitingThis phase 2 trial tests giving short course radiation therapy along with standard chemotherapy before surgery for stomach cancer. The goal is to see if this total neoadjuvant therapy leads to a higher rate of complete cancer disappearance, with fewer side effects than traditiona…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug beat radiation for early-stage lymphoma?
Disease control Not yet recruitingThis phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chanc…
Phase: PHASE3 • Sponsor: Australasian Leukaemia and Lymphoma Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a simple urine test spare bladder cancer patients from chemotherapy?
Disease control Not yet recruitingThis trial asks whether some people with intermediate-risk bladder cancer can safely skip chemotherapy after having their tumor removed. Doctors will use a urine test before surgery to find patients whose tumors are unlikely to shed detectable signals. These patients will then be…
Phase: NA • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug combo outsmart resistant lymphomas?
Disease control Not yet recruitingThis phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocyt…
Phase: PHASE2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Old drug, new hope: mercaptopurine tested against rare cancer syndrome
Disease control Not yet recruitingThis trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug combo shrink advanced colorectal tumors?
Disease control Not yet recruitingThis trial is testing whether an investigational drug called SYS6090, when combined with standard treatments like bevacizumab and chemotherapy, can safely and effectively treat advanced colorectal cancer that cannot be removed by surgery. The study includes adults with a specific…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new infusion drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called SM2275 in people with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard therapy exists. The study aims to find the safest dose, understand how the drug behave…
Phase: PHASE1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a smart drug deliver a toxic payload to prostate cancer cells?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent d…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a single injection curb blood loss in fibroid surgery?
Disease control Not yet recruitingThis trial tests whether injecting a diluted solution of terlipressin, a drug that narrows blood vessels, under the outer layer of a uterine fibroid before removal can reduce blood loss during myomectomy surgery. Women scheduled for myomectomy will be randomly assigned to receive…
Phase: NA • Sponsor: Sevil Cankaya • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a cancer biopsy predict who responds to a new immunotherapy?
Disease control Not yet recruitingThis phase 2 trial is testing the drug glofitamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Glofitamab is a type of immunotherapy that helps the body's T-cells attack cancer cells. The study uses tumor biopsies tak…
Phase: PHASE2 • Sponsor: Joshua Brody • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Five-Drug combo tame a tough lymphoma without standard chemo?
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of five drugs—chidamide, azacitidine, prednisone, cyclophosphamide, and thalidomide—can help people with peripheral T-cell lymphoma (PTCL) who are unable to tolerate standard chemotherapy. The study will enroll 58 adults with PT…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Cancer-Fighting virus shrink resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing an experimental virus called GO321, which is designed to infect and destroy cancer cells. The study involves adults with advanced solid tumors that have not responded to standard treatments. Participants receive GO321 as an injection directly int…
Phase: PHASE1 • Sponsor: GeneSail Biotech (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
CLL patients may get a break from daily pills
Disease control Not yet recruitingThis study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a breast cancer combo be safer for diabetics?
Disease control Not yet recruitingThis trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called birelentinib to standard chemotherapy (R-CHOP) improves outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Participants receive either birelentinib plus R-CHOP or a placebo plus R-CHOP. The s…
Phase: PHASE2, PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Personalized cell therapy takes on Hard-to-Treat tumors
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a single eye injection shrink melanoma and save sight?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called RBP-01 (sotrastaurin), given as an injection into the eye, for people with primary uveal melanoma—a rare cancer of the eye. The study aims to see if the drug is safe and whether it can shrink the tumor enough to avo…
Phase: PHASE1, PHASE2 • Sponsor: ReBio Pharma • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Drug combo keep fighting a rare ovarian cancer?
Disease control Not yet recruitingThis study offers continued access to an experimental combination of two oral drugs—avutometinib and defactinib—for people with recurrent low-grade serous ovarian cancer (LGSOC) who have already been benefiting from this treatment in a prior study. The goal is to allow uninterrup…
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
Disease control Not yet recruitingThis phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…
Phase: PHASE3 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a smart drug deliver a lethal payload to endometrial cancer?
Disease control Not yet recruitingThis study tests an experimental drug called TUB-040 in people with recurrent or progressive endometrial cancer that has not responded to platinum-based chemotherapy and immunotherapy. TUB-040 is an antibody-drug conjugate designed to bind to a protein called NaPi2B on cancer cel…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New immunotherapy targets rare cancers by harnessing the Body's immune system
Disease control Not yet recruitingThis phase 2 trial tests a new drug called brenetafusp (IMC-F106C) in people with rare cancers—synovial sarcoma and myxoid liposarcoma—that have spread or cannot be surgically removed. The drug is a type of immunotherapy designed to guide the body's immune cells to attack cancer …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingThis phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…
Phase: PHASE3 • Sponsor: Women's Cancer Study Group GmbH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Two-Drug combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the comb…
Phase: PHASE2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
Disease control Not yet recruitingThis phase 2 trial is investigating whether giving immunotherapy before surgery for advanced melanoma (stage IIIB to IV M1a) can maintain survival while allowing patients to skip the usual adjuvant therapy after surgery. Participants are randomly assigned to receive either two in…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a 'No-Touch' microwave technique match surgery for liver tumors?
Disease control Not yet recruitingThis study looks at three ways to treat subcapsular hepatocellular carcinoma (HCC), a type of liver cancer near the surface of the liver. It compares two minimally invasive microwave ablation methods—one that avoids piercing the tumor and one that does—against traditional surgica…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a probiotic boost breast cancer treatment? new trial aims to find out
Disease control Not yet recruitingThis Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
Disease control Not yet recruitingThis phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New endoscopic technique could simplify breast reconstruction after mastectomy
Disease control Not yet recruitingThis study will compare a newer, less invasive endoscopic breast reconstruction method (direct-to-implant) with traditional flap surgery (using tissue from the abdomen) in 588 women who had a mastectomy at least one year ago. The goal is to see if the endoscopic approach leads to…
Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…
Phase: NA • Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Two-Drug combo stop a rare, aggressive nerve tumor?
Disease control Not yet recruitingThis phase 2 trial is testing whether the combination of avutometinib and defactinib can stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery. The study enrolls people over 12 years old with relapsed, refractory, met…
Phase: PHASE2 • Sponsor: Girish Dhall, MD • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug GEN1119 aims to fight solid tumors that resist standard care
Disease control Not yet recruitingThis trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill outsmart RAS-Mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral drug called BG-85738 in people with advanced or metastatic solid tumors that have RAS mutations. The study aims to see if the drug is safe and tolerable when given alone or combined with other anti-cancer agents, and to get a…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Water jet surgery could offer new option for prostate cancer patients
Disease control Not yet recruitingThis study compares a robotic water-jet procedure called Aquablation to active surveillance (close monitoring) in 333 men with low- or intermediate-risk localized prostate cancer. The goal is to see if Aquablation can better prevent cancer from progressing to a more serious grade…
Phase: NA • Sponsor: PROCEPT BioRobotics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Triple-Drug combo tackle breast cancer brain metastases?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing bra…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New radiation technique may spare spine patients from surgery
Disease control Not yet recruitingThis study tests a precise, MRI-guided radiation treatment for people with cancer that has spread to the spine and is pressing on the spinal cord. The goal is to shrink the tumor enough to avoid surgery. About 24 adults with solid tumors like breast, prostate, or lung cancer will…
Phase: NA • Sponsor: University of Miami • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Heat-and-Freeze treatment plus a vaccine outsmart pancreatic cancer?
Disease control Not yet recruitingThis phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Color-Enhanced scope catch what white light misses?
Disease control Not yet recruitingThis trial tests whether a special light mode called linked color imaging (LCI) helps doctors find more sessile serrated lesions (a type of precancerous colon polyp) during colonoscopy than standard white light. About 2,000 adults aged 45 and older having their first screening co…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new drug combo shrink Hard-to-Treat colorectal tumors?
Disease control Not yet recruitingThis trial is testing whether an experimental drug called MRG007, given together with standard chemotherapy and targeted therapies, can safely shrink tumors in people with advanced colorectal cancer that cannot be removed by surgery. The study involves about 316 participants and …
Phase: PHASE1, PHASE2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can removing bladder tumors in one piece improve cancer outcomes?
Disease control Not yet recruitingThis trial tests whether a newer surgical method called en bloc resection, which removes bladder tumors in one piece, works better than the standard piecemeal approach for people with intermediate- or high-risk non-muscle-invasive bladder cancer. All participants also receive a y…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a biomarker spare breast cancer patients from harsh chemo?
Disease control Not yet recruitingThis trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo targets resistant tumors
Disease control Not yet recruitingThis study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart tough lung cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …
Phase: PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat adrenal tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a needle through the windpipe beat the knife for early lung cancer?
Disease control Not yet recruitingThis trial tests whether a minimally invasive procedure called bronchoscopic microwave ablation can be as effective as surgery for early-stage lung cancer (stage IA). The procedure uses a bronchoscope to guide a needle to the tumor and destroy it with heat, potentially preserving…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Drug punch shrink eyelid tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving two drugs—sintilimab and disitamab vedotin—before surgery can shrink tumors in people with a rare type of eyelid cancer called sebaceous gland carcinoma. Participants receive two cycles of the combination, then undergo surgery to remove the tu…
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a genetic trait stop chemotherapy from working? a trial aims to fix that
Disease control Not yet recruitingThis trial is testing whether a new dosing algorithm can help people with a genetic trait called Duffy-null get the full benefit of chemotherapy. Many people of African or Middle Eastern descent naturally have lower white blood cell counts (Duffy-null neutropenia), which can lead…
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Pronged immune attack shrink kidney tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving a combination of an experimental immunotherapy (epalolitoworelimab) and a targeted therapy (lenvatinib) before and after surgery can improve outcomes for people with high-risk clear cell kidney cancer. The treatment is given first to shrink th…
Phase: PHASE2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant ovarian cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two drugs—mirvetuximab soravtansine and suvemcitug—can help people with a type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 20 adults with FRα-positive, platinum-resistant recur…
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo strategy takes on Hard-to-Treat breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for advanced stomach cancer: drug combo plus radiation shows promise
Disease control Not yet recruitingThis study looks at a new treatment for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard therapies. It combines a targeted drug (disitamab vedotin) with immunotherapy and a special type of radiation. The goal is to see…
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced sarcoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple injection replace an IV for this myeloma drug?
Disease control Not yet recruitingThis trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a dual immunotherapy erase hidden myeloma cells?
Disease control Not yet recruitingThis phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…
Phase: PHASE3 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted drug combo outperform standard chemo for tough lung cancer?
Disease control Not yet recruitingThis trial is testing whether a new experimental drug called YL201, when combined with the immunotherapy serplulimab, can help people with extensive-stage small cell lung cancer live longer compared to the current standard treatment (carboplatin and etoposide plus serplulimab). T…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted radiation boost slow advanced lung cancer?
Disease control Not yet recruitingThis trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …
Phase: PHASE3 • Sponsor: Trans Tasman Radiation Oncology Group • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat GI cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…
Phase: PHASE1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a daily pill ease anemia in bone marrow disorders?
Disease control Not yet recruitingThis trial tests an experimental oral drug, ofirnoflast, in adults with lower-risk myelodysplastic syndromes (MDS) who have anemia and need regular red blood cell transfusions. The goal is to see if the drug can reduce or eliminate transfusion needs and improve blood counts. Part…
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new pill take on brain cancer?
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called CT-179 in people with glioblastoma, an aggressive brain cancer. The study has two parts: one for patients whose cancer has returned, and another for newly diagnosed patients who will also receive radiation therapy. The main…
Phase: PHASE1 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a novel drug combo outperform standard chemo for lung cancer?
Disease control Not yet recruitingThis trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Parent-Child workouts may boost activity in kids with leukemia
Disease control Not yet recruitingThis trial tests whether a parent-child physical activity program can increase exercise levels in children aged 9–18 with leukemia who are on maintenance therapy. Children and parents attend weekly exercise sessions together for three months. The study compares this approach to c…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Action antibody takes aim at advanced breast cancer
Disease control Not yet recruitingThis trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…
Phase: PHASE1, PHASE2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a novel drug combo outperform chemo in lung cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Ovarian suppression plus tamoxifen: a Long-Term bet against breast cancer recurrence
Disease control Not yet recruitingThis study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…
Sponsor: MedicalExcellence • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart High-Risk CLL?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 …
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
Disease control Not yet recruitingThis phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart a rare and aggressive cancer?
Disease control Not yet recruitingThis clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alon…
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a natural compound boost chemotherapy against endometrial cancer?
Disease control Not yet recruitingThis trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combinati…
Phase: PHASE2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a sound wave boost prostate cancer radiation precision?
Disease control Not yet recruitingThis trial is testing whether using microultrasound to guide a radiation boost to cancerous spots inside the prostate can reduce side effects compared to standard radiation therapy. Men with intermediate-risk prostate cancer will receive stereotactic body radiation therapy (SBRT)…
Phase: NA • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a simple CT scan catch lung cancer earlier in kuwait?
Diagnosis Not yet recruitingThis pilot study will offer low-dose CT scans to about 500 high-risk smokers aged 50-80 in Kuwait to see if this screening approach is practical and acceptable. The goal is to measure how many people agree to screening, identify barriers, and evaluate the use of AI to help read t…
Phase: NA • Sponsor: Sulaiman Khadadah • Aim: Diagnosis
Last updated Aug 18, 2026 03:00 UTC
-
Can a single injection reveal hidden kidney cancer?
Diagnosis Not yet recruitingThis early-stage trial tests an experimental imaging agent called 68Ga-NYM096 in 20 adults who have a kidney mass of uncertain nature seen on CT or MRI and are scheduled for surgery. The agent is designed to attach to a protein common on clear cell renal cell carcinoma cells, pot…
Phase: PHASE1 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Aug 18, 2026 03:00 UTC
-
Can AI be a second pair of eyes for liver cancer detection?
Diagnosis Not yet recruitingThis trial asks whether adding artificial intelligence (AI) to radiologists' reading of liver CT scans can match or improve standard reporting. It involves 40,000 adults who had contrast-enhanced CT scans of the abdomen. On some days, radiologists first read scans on their own, t…
Phase: NA • Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Aug 18, 2026 03:00 UTC
-
A new MRI approach could spare patients unnecessary lung biopsies
Diagnosis Not yet recruitingThis study explores whether a special MRI scan, done without any contrast dye, can tell the difference between benign and cancerous lung nodules that were flagged as suspicious on a routine lung cancer screening CT. Adults aged 50 to 80 with a history of heavy smoking and a Lung-…
Sponsor: University of Florida • Aim: Diagnosis
Last updated Aug 18, 2026 03:00 UTC
-
Can a new tracer light up hidden prostate cancer?
Diagnosis Not yet recruitingThis trial is testing an experimental imaging agent called [⁶⁴Cu]Cu-RAX301, which is designed to bind to prostate cancer cells and show up on PET/CT scans. The study includes men with prostate cancer who are either about to have surgery to remove the prostate or who may have a re…
Phase: PHASE1, PHASE2 • Sponsor: RadAlliance Therapeutics, Inc • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New PET tracer may reveal which bile duct cancers resist standard therapy
Diagnosis Not yet recruitingThis trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
A sharper eye on prostate cancer return: PSMA PET vs. MRI
Diagnosis Not yet recruitingThis pilot study investigates whether a PSMA PET scan, using an injected radiotracer, can detect clinically significant prostate cancer recurrence one year after focal HIFU treatment, compared with the standard MRI. About 30 men with prostate cancer who meet specific criteria wil…
Phase: PHASE4 • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a simple blood test spot ovarian cancer before it starts?
Diagnosis Not yet recruitingThis study is looking at whether a blood test called Galleri can help detect ovarian cancer early in people with BRCA1 or BRCA2 gene changes, who are at higher risk. Participants will give a blood sample and answer questionnaires about their experience. The study will also check …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a special PET scan spot hidden prostate cancer after focal therapy?
Diagnosis Not yet recruitingThis trial investigates whether Posluma, a PSMA-targeted PET scan, can accurately detect any remaining or returning prostate cancer about 12 months after focal therapy. Researchers will compare the scan results with MRI and biopsy data in 22 men with intermediate-risk, organ-conf…
Phase: PHASE2 • Sponsor: Aditya Bagrodia • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new imaging trick spot pancreatic cancer without a biopsy?
Diagnosis Not yet recruitingThis study looks at whether a special ultrasound technique called detective flow imaging (DFI) can help doctors tell the difference between benign and malignant solid pancreatic lesions. Researchers will examine the blood vessel patterns seen with this technique and compare them …
Sponsor: Julio Iglesias García • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Can a simple blood test outsmart deadly fungal infections in blood cancer?
Diagnosis Not yet recruitingThis study is testing whether a blood test called metagenomic next-generation sequencing (mNGS) can accurately diagnose invasive fungal disease in people with blood cancers. These patients are at high risk for such infections, which are often hard to detect and can become severe.…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
AI may help spot dangerous prostate cancer and spare men from needless biopsies
Diagnosis Not yet recruitingThis study tests a new AI framework called Cad-MMFF that combines clinical information, ultrasound, and MRI images to better detect clinically significant prostate cancer. The goal is to see if this approach can reduce unnecessary biopsies and safely limit the use of MRI. The stu…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New radioactive antibody could light up Hard-to-Treat cancers
Diagnosis Not yet recruitingThis early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Which lung biopsy method is safer and more accurate?
Diagnosis Not yet recruitingThis trial compares two established biopsy methods for small lung nodules (≤2 cm): CT-guided percutaneous biopsy and shape-sensing robotic-assisted bronchoscopy with cone-beam CT. The goal is to see which approach is more effective at diagnosing cancer and which has fewer complic…
Phase: PHASE4 • Sponsor: Intuitive Surgical • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
Diagnosis Not yet recruitingThis study investigates whether tiny particles shed by tumors into the blood, called extracellular vesicles, can serve as a non-invasive biomarker for metastatic colorectal cancer. Researchers will analyze blood samples from 290 patients at different treatment stages to see if th…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a tiny ultrasound probe see how deep a urinary tract tumor goes?
Diagnosis Not yet recruitingThis trial tests whether a specialized ultrasound catheter, normally used in heart arteries, can be safely threaded into the upper urinary tract to measure how deeply a tumor has invaded the wall. Fifteen adults with upper tract urothelial carcinoma who are already scheduled for …
Phase: NA • Sponsor: Yonsei University • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Could a new score spare men from unnecessary prostate biopsies?
Diagnosis Not yet recruitingThis study is testing whether a new scoring system, called the Fusion CEMEP score, can safely guide prostate biopsy decisions. The goal is to see if men with suspected prostate cancer can skip the extra systematic biopsies and only have targeted biopsies based on MRI findings. Th…
Sponsor: Marcelo Ruben Oliva • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Budget laparoscope could transform cancer diagnosis in Low-Resource countries
Diagnosis Not yet recruitingThis study tests a new, low-cost tool called KeyScope that helps doctors see inside the belly to diagnose cancer. It is designed for use in countries like Uganda where resources are limited. Twelve adults with suspected abdominal cancer will have a biopsy using this device. The m…
Phase: NA • Sponsor: Duke University • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
New blood marker duo could spot leukemia earlier
Diagnosis Not yet recruitingThis study investigates whether measuring two proteins, CD38 and CD56, on white blood cells called neutrophils can help diagnose chronic myeloid leukemia (CML). Researchers will compare the levels of these markers in 200 people with CML to see if a high percentage is a reliable s…
Sponsor: Sohag University • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
A sharper eye on prostate cancer: could new imaging spare healthy tissue?
Diagnosis Not yet recruitingThis pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
Glowing cancer cells: a new way to see tumors during surgery?
Diagnosis Not yet recruitingThis trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Liquid biopsies may let lynch syndrome patients skip half their colonoscopies
Diagnosis Not yet recruitingThis study tests whether annual liquid biopsies (from blood, urine, stool, and vaginal swabs) can safely replace colonoscopies every 18 months for people with Lynch syndrome. 2,000 participants will be split into two groups: one gets standard care (colonoscopy every 18 months), t…
Phase: NA • Sponsor: UNICANCER • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Hours, not weeks: a new test could speed up lymphoma diagnosis
Diagnosis Not yet recruitingThis trial tests whether a rapid lab technique called flow cytometry can quickly identify lymphoma from a small lymph node sample. People already undergoing a standard fine needle aspiration for suspected lymphoma will give an extra sample for this test. The goal is to see if thi…
Phase: NA • Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
AI eye on polyps: could a computer match the microscope?
Diagnosis Not yet recruitingThis trial tests whether an AI system called GI Genius can help doctors accurately tell apart small colorectal polyps (5 mm or less) during a colonoscopy—identifying which ones are harmless versus those that need monitoring. For each small polyp, doctors first record their own di…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
A new PET scan tracks brain tumors by their appetite for tryptophan
Diagnosis Not yet recruitingThis trial is testing whether a special PET/CT scan that uses a radioactive form of tryptophan can provide better information about gliomas (a type of brain tumor) than standard MRI. The study has three parts: seeing if the scan can better define the tumor for radiation planning,…
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Peer power: could community education boost cancer screening?
Prevention Not yet recruitingThis pilot trial tests a community-based program designed to help Chinese immigrants aged 45-75 get up-to-date on colorectal and breast cancer screening. The program includes a group education session led by a community health worker and personalized help navigating the healthcar…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug shield nerves from Chemotherapy's side effects?
Prevention Not yet recruitingThis phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…
Phase: PHASE2 • Sponsor: Sironax USA, Inc. • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Could deep breaths before surgery ward off Post-Op confusion?
Prevention Not yet recruitingThis study tests whether practicing deep breathing exercises before surgery can lower the chance of postoperative delirium—a state of confusion and disorientation—in men undergoing robot-assisted prostate removal for prostate cancer. Half of the 50 participants will be taught a s…
Phase: NA • Sponsor: ALİ DEMİRTAŞ • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Psilocybin trial aims to shield cancer patients from chemo nerve pain
Prevention Not yet recruitingThis Phase 2 trial tests whether psilocybin, a psychedelic compound, can prevent or lessen chemotherapy-induced peripheral neuropathy (nerve damage) in people with breast, colorectal, or head and neck cancer. About 83 participants will receive either psilocybin, a low-dose placeb…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
Prevention Not yet recruitingThis study tests whether it is practical and safe to remove the fallopian tubes during planned weight-loss (bariatric) surgery as a way to lower the risk of ovarian cancer. Many ovarian cancers are thought to start in the fallopian tubes, and removing them can reduce risk by abou…
Phase: EARLY_PHASE1 • Sponsor: St. Joseph's Healthcare Hamilton • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Ear acupressure: a new weapon against chemotherapy side effects?
Prevention Not yet recruitingThis trial tests whether adding auricular acupressure—using small seed patches on specific ear points—to standard antiemetic medication can better prevent nausea and vomiting in people receiving highly emetogenic chemotherapy. About 332 patients with solid tumors will be randomly…
Phase: NA • Sponsor: China Medical University, China • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Aspirin may fight Cancer-Causing inflammation in the womb
Prevention Not yet recruitingThis study tests whether taking low-dose aspirin can lower inflammation in the womb lining and help prevent endometrial cancer. It involves 25 postmenopausal women who have non-atrophic endometrial changes and pain. Participants will be randomly assigned to take aspirin or not, a…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Could a Self-Collection kit in the ER help prevent cervical cancer?
Prevention Not yet recruitingThis pilot study aims to see if offering self-collection kits for cervical cancer screening and HPV vaccination in emergency departments can reach women who have limited healthcare access. Researchers will enroll 100 women aged 18-65 and track how many participate and complete th…
Sponsor: Mayo Clinic • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Can text messages or nurse visits boost breast cancer screening?
Prevention Not yet recruitingThis trial tests two approaches to encourage women in Ghana to get breast exams: one uses community health nurses to provide repeated educational sessions, and the other sends text messages about breast cancer screening. Both run over five months, and the study will compare them …
Phase: NA • Sponsor: University of Huddersfield • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
Can a common supplement stop colon polyps? new trial aims to find out
Prevention Not yet recruitingThis early-stage trial tests whether a daily supplement called SAMe can help prevent colorectal polyps (precursors to colon cancer) in 18 adults who have already had surgery for early-stage colon cancer. Participants will take SAMe for up to a year while researchers monitor for s…
Phase: PHASE1 • Sponsor: Jun Gong, MD • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
AI chatbot aims to demystify prostate cancer radiation — a trial puts it to the test
Symptom relief Not yet recruitingThis trial tests whether an artificial intelligence chatbot can help men with prostate cancer better understand radiation therapy. Participants will use a plain-language chatbot alongside standard education from their care team. Researchers will measure changes in patients' confi…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
Music as medicine: could ukulele lessons rebuild young brains after cancer?
Symptom relief Not yet recruitingThis study tests whether a year of music training can improve thinking, memory, and quality of life in children who have recovered from brain tumors. About 236 children aged 7-16 will either receive regular care or join a ukulele program with weekly group and online sessions. Res…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
Can everyday moisturizers soothe cancer Therapy's skin toll?
Symptom relief Not yet recruitingThis trial tests whether cosmeceutical moisturizers can ease skin dryness in people with cancer who experience skin side effects from treatments like chemotherapy or immunotherapy. Participants apply the moisturizers daily for 2-4 weeks and report changes in dryness severity. The…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
Can simple seated exercises boost strength and Well-Being during leukemia treatment?
Symptom relief Not yet recruitingThis trial tests whether a structured seated exercise program can help men with leukemia maintain functional capacity and quality of life during chemotherapy. Participants will do supervised, moderate-intensity seated exercises during their chemo cycles, with outcomes measured by…
Phase: NA • Sponsor: Suez University • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
New study tests simple home program to fight fatigue in breast cancer survivors
Symptom relief Not yet recruitingThis study looks at whether a 6-week home program combining exercise and a limited eating window is practical and helpful for breast cancer survivors who are on hormone therapy and feel fatigued. Twenty participants will follow a plan to increase their steps, do resistance band e…
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
Could a nerve zap stop cancer wasting? early trial tests device for cachexia
Symptom relief Not yet recruitingThis early-phase trial tests whether a device that blocks signals from the vagus nerve can safely help patients with metastatic pancreatic cancer who are experiencing severe weight loss (cachexia). The device is placed on the skin over the nerve and is used alongside chemotherapy…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Digital peer support: a new weapon against cancer treatment anxiety?
Symptom relief Not yet recruitingThis trial tests whether a mobile app that encourages social sharing and peer interaction can reduce anxiety and depression in people with head and neck cancer undergoing radiotherapy. Half of the 120 participants will use the app for eight weeks, while the other half receives a …
Phase: NA • Sponsor: West China Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Symptom relief Not yet recruitingThis study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Could sitting up make radiation therapy more comfortable?
Symptom relief Not yet recruitingThis study asks whether sitting upright during radiation therapy feels better than the standard lying-down position. People receiving radiation therapy, along with their caregivers, will try both positions and share their comfort levels and preferences. The goal is to see if upri…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Wearable vest aims to boost milk flow and prevent blocked ducts
Symptom relief Not yet recruitingThis trial tests a wearable vest that uses heat, massage, and vibration to stimulate milk flow in mothers who have had a cesarean delivery and whose babies are in the NICU. Participants use the vest three times daily for 10 days, alongside standard lactation care. The study measu…
Phase: NA • Sponsor: Selcuk University • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can acupuncture soothe the mind and body in breast cancer?
Symptom relief Not yet recruitingThis trial tests whether personalized acupuncture—chosen together by the patient and clinician—can ease psychosomatic symptoms like anxiety, depression, sleep problems, and fatigue in women with breast cancer. Participants are divided into groups based on their symptom patterns a…
Phase: NA • Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Exercise during chemo: a new weapon to preserve strength?
Symptom relief Not yet recruitingThis trial tests whether a supervised exercise program is practical and safe for women with early-stage breast cancer receiving chemotherapy before surgery. Participants either join a supervised aerobic and strength training program twice a week during chemo, or receive usual car…
Phase: NA • Sponsor: King Hamad University Hospital, Bahrain • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
One injection or many? a test to ease breast surgery pain
Symptom relief Not yet recruitingThis trial asks whether a single nerve block can match the pain relief of multiple nerve blocks after breast cancer surgery. Women aged 18-65 scheduled for breast cancer surgery will receive either one or several injections of a local anesthetic near the spine. The study measures…
Phase: NA • Sponsor: Antalya City Hospital • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Free money for cancer patients: $1,000 monthly cash cards tested in new study
Symptom relief Not yet recruitingThis pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Virtual therapy may ease breast cancer treatment side effects
Symptom relief Not yet recruitingThis study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can talking about meaning help stem cell transplant recovery?
Symptom relief Not yet recruitingThis study tests whether a seven-session, telehealth-based therapy called Meaning-Centered Psychotherapy is practical and helpful for stem cell transplant survivors and their main caregivers. The program aims to help dyads stay connected to meaning, cope with difficult experience…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a stronger radiation dose ease bulky tumors better?
Symptom relief Not yet recruitingThis study compares standard palliative radiotherapy (24 Gray in 3 sessions) with a higher dose (27 Gray in 3 sessions) for people with large metastatic tumors. The goal is to see if the higher dose improves tumor control without more side effects. About 20 adults with solid tumo…
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
Symptom relief Not yet recruitingThis phase III trial is testing whether adding aromatherapy—using lemon, lavender, and peppermint essential oils—to standard anti-nausea medication can better prevent nausea and vomiting in breast cancer patients receiving highly emetogenic chemotherapy. About 374 patients will b…
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Estrogen patch may ease hot flashes in prostate cancer treatment
Symptom relief Not yet recruitingThis study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a virtual wellness program help women with advanced breast cancer?
Symptom relief Not yet recruitingThis study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Magic mushroom compound tested for cancer pain relief
Symptom relief Not yet recruitingThis phase II trial tests whether low-dose psilocybin, a compound from magic mushrooms, combined with psychotherapy is safe and effective for easing chronic pain in cancer patients who already take opioids. Twenty adults with active cancer and moderate to severe pain will receive…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Glow-in-the-Dark dye could save voices in thyroid surgery
Symptom relief Not yet recruitingThis phase 2 trial tests a dye called bevonescein that makes nerves glow during thyroid surgery, helping surgeons see and avoid them. Forty adults having thyroid removal will receive the dye before surgery. The main goal is to see if it improves voice outcomes by reducing nerve i…
Phase: PHASE2 • Sponsor: Matthew Spector • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Nature escapes in a headset: a new way to calm cancer infusions?
Symptom relief Not yet recruitingThis randomized trial tests whether immersive virtual reality (VR) can reduce anxiety in people with lung cancer during immunotherapy or chemo-immunotherapy infusions. Half of the 60 participants will use a VR headset showing calming nature scenes during four infusion visits, whi…
Phase: NA • Sponsor: Dott.Claudio Sini • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
Symptom relief Not yet recruitingMany cancer patients feel anxious before radiotherapy, partly due to unfamiliar equipment and procedures. This trial tests whether adding a simulation-based education session — a virtual preview of the treatment environment — before standard education can reduce that anxiety and …
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a simple cough exercise restore strength after head and neck cancer?
Symptom relief Not yet recruitingThis study tests whether a cough skill training program can help people with head and neck cancer cough more effectively. Participants practice voluntary coughs using a handheld device during sessions and at home. The goal is to see if the training is feasible and if it improves …
Phase: NA • Sponsor: Boston University Charles River Campus • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Could a tiny dose of naltrexone beat cancer fatigue?
Symptom relief Not yet recruitingThis phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New study aims to help lymphoma survivors thrive after cancer
Symptom relief Not yet recruitingThis study tests whether a resilience-building program can improve quality of life for lymphoma survivors who finished treatment within the last two years. Researchers will compare the program to a standard health education class. The goal is to help survivors feel better physica…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Chatbot coach for cancer care: new study tests digital sidekick for lung patients
Symptom relief Not yet recruitingThis study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients handle side effects from their targeted therapy. About 178 adults with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot bo…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Brain fog after cancer: can a group program sharpen the mind?
Symptom relief Not yet recruitingThis pilot trial tests a structured cognitive rehabilitation program called CanCOG® for cancer survivors who experience thinking difficulties—often called 'chemo brain'—after treatment for cancers outside the brain. Sixty adult survivors will be randomly assigned to either the si…
Phase: NA • Sponsor: Aveiro University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Zapping pain away: new device could help kids with cancer ditch pain pills
Symptom relief Not yet recruitingThis study tests a device called Scrambler Therapy to relieve nerve pain in children with cancer that has spread to the bone. The treatment is non-invasive and aims to lower pain levels and reduce the need for pain medications. About 70 children who can describe their pain will t…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
Symptom relief Not yet recruitingThis trial tests whether a home-based, digitally supervised prehabilitation program—using 5G and AI—can help gastric cancer patients get fitter before surgery. Participants who have completed chemotherapy and are scheduled for stomach removal will either receive standard care or …
Phase: NA • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A new program aims to help teens thrive when a parent faces cancer
Symptom relief Not yet recruitingThis study is testing a family-centered program called SHINE, designed to support teenagers aged 10 to 17 who have a parent diagnosed with cancer. The program includes about four sessions over eight weeks, focusing on cancer education, family communication, coping skills, and emo…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Brain training game aims to boost processing speed in young cancer survivors
Symptom relief Not yet recruitingThis study tests whether a simple online computer game can help children with brain tumors think faster. 300 kids will do 15 minutes of cognitive training, 5 times a week for 8 weeks. Researchers will check if the training is easy to do at home and if it actually improves process…
Phase: NA • Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Talking about sex after cancer: telehealth therapy may improve recovery
Symptom relief Not yet recruitingThis study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Can a few weeks of intense exercise boost prostate surgery recovery?
Symptom relief Not yet recruitingThis pilot study tests whether high-intensity interval training (HIIT) before prostate removal surgery can improve recovery and reduce anxiety. Men scheduled for radical prostatectomy will do vigorous exercise for about 60 minutes per week for at least four weeks before their ope…
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New support program aims to help breast cancer patients stick with treatment
Symptom relief Not yet recruitingThis study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Facing the fear: can talk therapy help couples live beyond cancer?
Symptom relief Not yet recruitingThis trial tests whether a type of talk therapy called Acceptance and Commitment Therapy (ACT) can help cancer survivors and their spouses cope with the fear that cancer might return. It compares ACT to a more traditional therapy, Cognitive Behavioural Therapy (CBT), in a two-arm…
Phase: NA • Sponsor: University Center of Tumor Diseases, Frankfurt University Hospital • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
AI therapy coach aims to ease distress in seriously ill seniors
Symptom relief Not yet recruitingThis study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Music may soothe pain at the genetic level after cancer surgery
Symptom relief Not yet recruitingThis study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
New app aims to ease recovery after cancer surgery
Symptom relief Not yet recruitingThis study tests a digital tool called RECapp that helps patients recover after surgery for esophageal or stomach cancer. The app lets patients track symptoms, get personalized self-care advice, and know when to contact their healthcare team. 250 adults in Sweden will use the app…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Robot companions may soothe cancer Patients' emotional turmoil
Symptom relief Not yet recruitingThis trial tests a supportive care program called E-MOTE, delivered by an AI-assisted robot during hospital stays and a mobile app after discharge, for women newly diagnosed with gynecologic cancer who are undergoing surgery. The program includes emotional assessments, empathetic…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Exercise after chemo: could a simple walking program protect your heart?
Symptom relief Not yet recruitingThis study looks at whether an 8-week aerobic exercise program can improve blood vessel function in women who have finished chemotherapy for non-metastatic breast cancer. Forty women will exercise three times a week for 30 minutes at a moderate pace. Researchers will measure arte…
Phase: NA • Sponsor: Loyola University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could gentle yoga and breathing ease Cancer's lingering toll?
Symptom relief Not yet recruitingThis trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can an AI chatbot ease fertility worries for young cancer survivors?
Symptom relief Not yet recruitingThis pilot trial tests whether a chatbot powered by large language models can help adolescent and young adult cancer survivors address reproductive concerns. Participants will be randomly assigned to use the chatbot or read an electronic brochure with similar information. The stu…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
A single zoom class might ease cancer pain for american indians
Symptom relief Not yet recruitingThis trial tests whether a single, two-hour online class called Empowered Relief can help American Indian adults with cancer-related pain. Participants learn three pain relief skills, create a personal plan, and get access to a free audio app for daily practice. The study aims to…
Phase: NA • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Fighting sedentary time in young cancer patients: a digital intervention put to the test
Symptom relief Not yet recruitingThis trial tests whether a 10-week mobile health program, called ReSeT2, can reduce the time adolescents and young adults with acute lymphoblastic leukemia (ALL) spend sitting during maintenance therapy. Participants aged 13-22 will be randomly assigned to either the intervention…
Phase: NA • Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Teamwork in care: could shared Self-Care lessons ease the toll of breast cancer treatment?
Symptom relief Not yet recruitingThis trial tests whether a structured education program, given to both breast cancer patients and their primary caregivers together, can improve self-care behaviors and reduce anxiety for patients, while also easing caregiver anxiety and burden. The program involves four weekly s…
Phase: NA • Sponsor: Ulviye Aydan NACAK • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Brain games may rev up thinking and driving after cancer treatment
Symptom relief Not yet recruitingThis study tests whether a 10-week home-based video game training program can improve cognitive function and driving performance in head and neck cancer survivors who report thinking difficulties after radiation or chemoradiation. Participants will complete questionnaires, use a …
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can a new anesthetic give older surgery patients a better Night's sleep?
Symptom relief Not yet recruitingThis trial tests whether remimazolam, an anesthetic drug, can improve sleep quality in older adults after laparoscopic colorectal cancer surgery, compared with the standard anesthetic propofol. Participants aged 65-80 will be randomly assigned to receive one of the two anesthetic…
Phase: NA • Sponsor: General Hospital of Ningxia Medical University • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
AI reads your cancer care wishes — could it keep you out of the hospital?
Symptom relief Not yet recruitingThis trial tests whether sending AI-generated summaries of a patient's serious illness conversations to their care team at hospital admission can improve care. The summaries, created by a large language model, highlight the patient's goals and preferences. The study enrolls adult…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Can pancreatic Cancer's inflammatory footprint be stopped?
Knowledge-focused Not yet recruitingThis observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Spinal fluid may hold clues to breast cancer brain spread
Knowledge-focused Not yet recruitingThis study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Blood tests could reveal who benefits from Next-Gen lymphoma antibodies
Knowledge-focused Not yet recruitingThis observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adul…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Can AI craft the perfect exercise plan for breast cancer survivors?
Knowledge-focused Not yet recruitingThis study explores whether a large language model (AI) can generate personalized exercise prescriptions for people recovering from breast cancer surgery. Researchers will collect health and fitness data from 40 postoperative patients and use the AI to create exercise plans. Expe…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Could a simple scan and blood test outsmart liver cancer?
Knowledge-focused Not yet recruitingThis study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …
Sponsor: D'Or Institute for Research and Education • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Magnetic dye trial aims to spot hidden stomach cancer spread
Knowledge-focused Not yet recruitingThis early-stage study tests whether a magnetic tracer and a fluorescent dye can safely help doctors find lymph nodes where stomach cancer may have spread. About 20 adults with early stomach cancer will receive the injection before surgery. The goal is to see if this method is sa…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New program aims to bridge the trust gap between oncologists and latino patients
Knowledge-focused Not yet recruitingThis study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New study tracks Real-World impact of fruquintinib on advanced colon cancer
Knowledge-focused Not yet recruitingThis study will follow 110 adults in Poland with metastatic colorectal cancer (cancer that has spread) who are taking fruquintinib after at least two prior treatments. Researchers will track how long patients live without their cancer getting worse and their overall survival, usi…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can 3D-Printed models unlock personalized blood cancer therapies?
Knowledge-focused Not yet recruitingThis study aims to create 3D models of B-cell cancers—like chronic lymphocytic leukemia, splenic marginal-zone lymphoma, and hairy cell leukemia—using blood samples from patients. The goal is to build realistic models that mimic the tumor environment, which could help researchers…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Blood and gut clues may flag pancreatic cancer risk early
Knowledge-focused Not yet recruitingThis observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…
Sponsor: Changhai Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New study tracks hidden dangers of common leukemia drug
Knowledge-focused Not yet recruitingThis study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Which rectal cancer surgery preserves quality of life better? a study investigates
Knowledge-focused Not yet recruitingThis study looks at people who had surgery for advanced lower rectal cancer, comparing two procedures: one that removes the rectum and anus (requiring a permanent stoma) and one that removes the rectum but keeps the anus (with a reconnection). The goal is to see which approach le…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New study aims to close racial gap in breast cancer screening
Knowledge-focused Not yet recruitingThis study tests whether a culturally tailored program can help Black women keep their mammogram appointments. About 176 women aged 40 and older who are scheduled for a screening mammogram will take part. The goal is to find better ways to reduce racial disparities in breast canc…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a smart tool keep watch on leukemia after treatment stops?
Knowledge-focused Not yet recruitingThis study explores whether a digital tool can help monitor adults with chronic myeloid leukemia who have stopped treatment for up to two years. Over 12 months, researchers will track how often patients use the tool, aiming for a usage rate of at least 60%. The goal is to see if …
Phase: NA • Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Vaping vs. smoking weed: which delivers THC faster?
Knowledge-focused Not yet recruitingThis study will compare how quickly and how much THC enters the blood when people vape THC liquids versus smoking cannabis. Forty healthy adults who already use both products will try each method in a random order. Researchers will measure THC levels, side effects, and puffing be…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Blood test may foretell Radiation's toll on the gut
Knowledge-focused Not yet recruitingThis observational study is investigating whether a blood marker called GLP-2 could help predict the risk and severity of acute radiation enteritis—a common and painful side effect of radiation therapy to the abdomen or pelvis. Researchers will measure GLP-2 levels in 50 adults b…
Sponsor: Wang Xinying • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
Knowledge-focused Not yet recruitingThis observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can better HER2 classification improve breast cancer care?
Knowledge-focused Not yet recruitingThis study looks at breast cancer tumors to understand HER2 levels, including low and ultra-low expressions, which may affect treatment choices. Researchers will examine tissue samples from 100 patients diagnosed in Sohag, Egypt, and compare HER2 status with other tumor features …
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
Knowledge-focused Not yet recruitingThis study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New imaging study aims to unlock HER2 secrets in lung cancer
Knowledge-focused Not yet recruitingThis study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…
Phase: PHASE1 • Sponsor: The Netherlands Cancer Institute • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can biological signals explain mastocytosis symptoms?
Knowledge-focused Not yet recruitingThis study aims to understand how symptoms of indolent systemic mastocytosis relate to biological signals in the body. Researchers will collect samples and data from 25 participants over 12 weeks to see how different treatments affect these signals. The goal is to improve underst…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
Knowledge-focused Not yet recruitingThis study aims to create new laboratory models of ovarian cancer that no longer respond to standard platinum-based chemotherapy or PARP inhibitors. Researchers will take tumor tissue from patients with resistant disease and grow it in mice and in the lab to mimic real clinical c…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study explores social factors in prostate cancer care for black immigrant men
Knowledge-focused Not yet recruitingThis study aims to understand how migration history and social factors affect the quality of life of Black immigrant men from Sub-Saharan Africa and the Caribbean who have been diagnosed with prostate cancer. Researchers will interview 40 men to learn about their experiences and …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can Immunotherapy's hidden toll on daily life be measured?
Knowledge-focused Not yet recruitingThis study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to …
Sponsor: Göteborg University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Your gut bacteria might hold the key to lung cancer treatment
Knowledge-focused Not yet recruitingThis study is exploring whether the bacteria in your gut can predict how well a certain type of lung cancer responds to treatment. Researchers are following 100 people with stage II-IIIB non-small cell lung cancer who are receiving chemoimmunotherapy before surgery. The goal is t…
Sponsor: Guangdong Provincial People's Hospital • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
A simple blood draw could spare kids with leukemia from painful bone marrow tests
Knowledge-focused Not yet recruitingThis study looks at whether a blood test that detects tumor DNA (ctDNA) can give the same information as bone marrow tests in children with acute leukemia. Researchers will compare ctDNA results with standard bone marrow checks for minimal residual disease. The goal is to see if …
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Six-Gene clue: could a simple test forecast lung spread in breast cancer?
Knowledge-focused Not yet recruitingThis study is testing whether a six-gene risk score, calculated from a tumor tissue sample, can predict which women with early-stage breast cancer are more likely to develop lung metastasis. Researchers will follow 330 women aged 18 to 70 for up to 120 months, tracking lung metas…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could a simple skin test replace bone marrow biopsies?
Knowledge-focused Not yet recruitingThis study explores whether a non-invasive, painless skin measurement called electrical bioimpedance can help monitor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). About 25 adults who are already scheduled for a bone marrow biopsy will also receive this skin te…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Bone scans may reveal how breast cancer subtypes spread
Knowledge-focused Not yet recruitingThis observational study looks at whether different molecular subtypes of breast cancer—like Luminal A, HER2-enriched, and triple-negative—show distinct patterns of bone metastasis on bone scans. Researchers will compare imaging results from 100 adults with breast cancer to see i…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Engineering immune cells to outsmart Leukemia's defenses
Knowledge-focused Not yet recruitingThis study investigates how to engineer T cells to more effectively target acute myeloid leukemia (AML). Researchers will analyze samples from healthy donors and AML patients to identify T-cell receptors that recognize leukemia cells. The goal is to create next-generation enginee…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
A new clue in the fight against colorectal cancer recurrence?
Knowledge-focused Not yet recruitingThis study looks at whether a combination of immune cell activity, genetic changes, and imaging features can help predict if colorectal cancer that has spread to the liver will come back after surgery. Researchers will analyze tumor tissue, blood samples, and scans from about 210…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Kidney transplant experiment halted before it began
Knowledge-focused Not yet recruitingThis study planned to test whether kidneys with small, low-risk tumors could be removed from donors, have the tumor taken out, and then be transplanted into patients with kidney failure. The goal was to increase the number of available donor kidneys. However, the study was withdr…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill rewrite the genetic story of resistant kidney cancer?
Knowledge-focused Not yet recruitingThis pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…
Phase: EARLY_PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Radon education program aims to empower cancer survivors and their communities
Knowledge-focused Not yet recruitingThis study tests whether a short educational presentation about radon can improve knowledge and encourage testing among cancer survivors, their caregivers, and family members. Participants attend a single session, either in person or online, led by a study staff member. The goal …
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can an app help older leukemia patients track their health at home?
Knowledge-focused Not yet recruitingThis pilot study tests whether adults aged 65 and older with acute leukemia can use a digital platform to complete health questionnaires from home. Twenty participants will fill out surveys about their quality of life and symptoms on a tablet or phone, with results sent directly …
Phase: NA • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can we end stigma in cancer care? a new study investigates
Knowledge-focused Not yet recruitingThis study asks whether healthcare providers in cancer centers hold negative attitudes toward patients with mental disorders, and what factors influence those views. Researchers will survey about 1,000 oncology professionals using a stigma questionnaire and interview some of them…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New study aims to unlock secrets of lung cancer drug through blood tests
Knowledge-focused Not yet recruitingThis study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New digital tool aims to help young cancer patients discuss fertility and relationships with doctors
Knowledge-focused Not yet recruitingThis study tests a digital tool called ReSPECT that helps teens and young adults with cancer talk to their doctors about sexual and reproductive health. The tool includes a pre-visit checklist and an informational website. Researchers want to see if it is practical and helpful fo…
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can artificial intelligence think like a cancer tumor board?
Knowledge-focused Not yet recruitingThis study asks whether an artificial intelligence system can make the same care recommendations as a team of cancer experts for people with stomach, colon, or rectal cancer. About 69 participants will have their medical information reviewed independently by both the AI and a mul…
Sponsor: Shanghai Minimally Invasive Surgery Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Blood test may decide who needs surgery for rectal cancer
Knowledge-focused Not yet recruitingThis phase 2 trial tests whether a highly sensitive blood test (ctDNA) can help manage treatment for 200 people with early-stage rectal cancer. After standard chemotherapy and radiation, some patients will have their treatment guided by the blood test results instead of immediate…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Could a simple test spot oral cancer and gum disease early?
Knowledge-focused Not yet recruitingThis study aims to find biological markers in saliva, mouth rinse, blood, or tissue that could help identify and predict the course of oral cancer, gum disease, and tooth decay. Researchers will collect health information and samples from 4,000 adults with these conditions and he…
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Bladder preservation: a viable alternative to radical surgery?
Knowledge-focused Not yet recruitingThis registry study follows bladder cancer patients who, after receiving systemic therapy, choose not to undergo bladder removal (cystectomy) or radiotherapy. The goal is to collect data on their outcomes, such as metastasis-free survival, to better understand which patients migh…
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Could a protein blocker quiet Leukemia's alarm system?
Knowledge-focused Not yet recruitingThis study investigates whether blocking a protein called IRAK4 can disrupt TLR signaling in leukemia cells from people with chronic lymphocytic leukemia (CLL). Researchers will collect extra blood samples from 50 adults with CLL during routine blood tests. In the lab, they will …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
MRI scans may reveal hidden clues to myeloma relapse risk
Knowledge-focused Not yet recruitingThis study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely t…
Sponsor: Fondazione EMN Italy Onlus • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Cancer Patients' decisions shaped by drug benefit uncertainties, study finds
Knowledge-focused Not yet recruitingThis study investigates how providing information about uncertainties in new cancer drugs' benefits influences patients' hypothetical treatment decisions and perceptions. Researchers will present current or former cancer patients with a scenario about a new drug called Zenova, wh…
Phase: NA • Sponsor: London School of Economics and Political Science • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Texting cancer patients after hospital stays may cut ER visits
Knowledge-focused Not yet recruitingThis study tests whether sending automated messages to cancer patients after they leave the hospital can help them use urgent oncology care instead of the emergency room. About 200 patients will receive reminders via MyChart and text in English or Spanish. Researchers will track …
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Brazil tests lung cancer screening in smokers
Knowledge-focused Not yet recruitingThis study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary fol…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
Knowledge-focused Not yet recruitingThis trial explores whether a training program for general practitioners can improve how primary care clinics deliver palliative care to adults with advanced cancer, COPD, heart failure, or kidney disease. One family health unit will use the new approach—a 30-hour e-learning cour…
Phase: NA • Sponsor: University of Coimbra • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Which High-Tech camera is better at spotting skin cancer?
Knowledge-focused Not yet recruitingThis study compares two total body photography systems used to screen for melanoma, a serious skin cancer. One system, Deviskan, takes automated images with non-contact dermoscopy, while the other, Vectra WB360, uses 3D photography with manual dermoscopy. Researchers will ask 60 …
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can a glowing drug light up head and neck tumors?
Knowledge-focused Not yet recruitingThis early-phase trial is testing whether injecting a fluorescently labeled version of the immunotherapy drug nivolumab directly into head and neck tumors is safe and helps visualize the tumor and nearby lymph nodes during surgery. Adults with head and neck squamous cell carcinom…
Phase: EARLY_PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
New blood test may spot hidden pancreatic cancer earlier after surgery
Knowledge-focused Not yet recruitingThis study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Ancient wisdom meets modern oncology: can TCM body types forecast treatment side effects?
Knowledge-focused Not yet recruitingThis study is looking at whether a person's traditional Chinese medicine (TCM) constitution—a concept that categorizes individuals into different body types—can help predict who will experience diarrhea as a side effect of combined immunotherapy and targeted therapy for liver can…
Sponsor: Affiliated Hospital of Chengde Medical University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Does a Thigh-Based breast reconstruction hold up over time? a study investigates
Knowledge-focused Not yet recruitingThis observational study examines long-term quality of life and aesthetic outcomes in women who underwent breast reconstruction using a PAP flap — a technique that uses tissue from the inner thigh. Researchers will survey participants and analyze photos to understand satisfaction…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple checklist boost recovery after cancer surgery?
Knowledge-focused Not yet recruitingThis pilot study tests whether surgeons will use a new set of timeline-specific guidelines designed to improve functional recovery after high-risk abdominal cancer surgery. Researchers will monitor how often surgeons follow the guideline in clinic. The goal is to see if such a to…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Lung cancer study seeks to map patient journeys
Knowledge-focused Not yet recruitingThis study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…
Sponsor: Janssen-Cilag Farmaceutica Ltda. • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
Knowledge-focused Not yet recruitingThis study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…
Sponsor: HAN GUANG • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can a Child's own words improve cancer care?
Knowledge-focused Not yet recruitingThis study asks whether a simple questionnaire, called SSPedi, can capture the symptoms that children with brain or spinal cord tumors experience while on new cancer therapies. Children aged 2 to 18 who are already part of a larger French study (SACHA) will use an app to report t…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Does CAR-T therapy affect the brain? a study investigates
Knowledge-focused Not yet recruitingThis study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. T…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can a website empower endometrial cancer patients?
Knowledge-focused Not yet recruitingThis study aims to develop an online educational tool for women diagnosed with endometrial cancer. Participants will use a website to access educational content, complete surveys, and provide feedback on its usability. The goal is to create a resource that can be made widely avai…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Olive oil and xylitol mouth rinse may shield cancer patients from painful mouth sores
Knowledge-focused Not yet recruitingThis study looks back at the medical records of 60 adults with head and neck cancer who received radiation therapy, with or without chemotherapy, and used a topical mouth rinse made from olive oil, betaine, and xylitol. The goal is to see how often severe mouth sores (oral mucosi…
Sponsor: Mucosa Innovations, S.L. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can immune profiling unlock the hidden stages of tuberculosis?
Knowledge-focused Not yet recruitingThis study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could…
Sponsor: Irene Latorre Rueda • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Bladder cancer surgery: what happens after the bladder is removed?
Knowledge-focused Not yet recruitingThis study looks at the well-being and medical care of people in Korea who had their bladder removed (radical cystectomy) for bladder cancer. Using nationwide insurance records, researchers will track complications, hospital stays, readmissions, and survival up to three years aft…
Sponsor: Janssen Korea, Ltd., Korea • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC